Your fact-checks will appear here
Medicine regulation agency in the UK
Most UK sources and international public-health summaries say common side effects after recent COVID‑19 vaccines in older adults are mild and short‑lived — arm soreness, fatigue, fever, headache and m...
Public reporting in the supplied sources documents many high-profile accusations and public statements by Michael Yeadon in 2023–2024 alleging wrongdoing by Pfizer, regulators and governments (example...
Regulatory agencies publicly rebutted or dismissed several early Yeadon claims in 2020–2021—most notably his petition to the European Medicines Agency and assertions about infertility and vaccine safe...
The MHRA’s April 30, 2025 announcement authorised a subcutaneous (under‑the‑skin) formulation of nivolumab for use across a broad range of solid‑tumour indications and stated the approval covers 15 ca...
Available reporting and studies from 2024–2025 show that most 2025 booster formulations (mRNA and protein‑subunit types) produce short‑lived local and systemic side effects — typically soreness, fatig...
Available sources do not mention a product called “Neurocept Astroncaps” and contain no international regulatory rulings specific to that name; reporting instead references Neurocrine Biosciences’ mar...
Available sources in the provided set show no mention that a drug or product named “Laellium” has received FDA or other regulatory approval; searches of December 2024–2025 FDA approval roundups and dr...
Reports of deaths linked to weight‑loss drugs are documented in reputable reporting, but available sources show a mix of contexts — some deaths involve unlicensed or compounded copies, others are repo...
A large new systematic review and meta‑analysis published in The Lancet Obstetrics, Gynaecology & Women’s Health concluded that prenatal paracetamol use is not associated with autism, ADHD, or intelle...
Regulatory agencies have issued warnings about non–FDA‑approved fat‑dissolving injections (often called "lipo," "lipodissolve," or similar), but the provided reporting contains no direct evidence of a...
The NHS has begun rolling out an under‑the‑skin injectable form of the immunotherapy drug nivolumab (Opdivo) that regulators have approved as an alternative to the intravenous infusion, and NHS Englan...
Serotonin syndrome after methylene blue exposure presents with a characteristic triad of mental-status changes, autonomic instability, and neuromuscular hyperactivity and most commonly occurs when met...
Available sources show only consumer reviews, marketing pieces, and broader regulatory commentary about neurotechnology — none document any formal regulatory agency review or decision specifically for...
Available sources do not mention a product or ingredient named “garaherb,” and there is no direct regulatory or certification information about it in the materials provided (not found in current repor...
State boards of pharmacy in each U.S. state (for example the California State Board of Pharmacy) are the primary authorities that license pharmacies and pharmacists and maintain searchable license dat...
Available search results do not show any recalls or safety alerts specifically mentioning a product named "gelatide" by the EMA, MHRA or Health Canada; the public databases and guidance pages from tho...
Available reporting and studies in the provided materials do not support the claim that mRNA COVID-19 vaccines cause a widespread “batch” injury in healthy adult males; surveillance and regulatory sta...
Salbutamol (also called albuterol) is an effective, widely used short‑acting beta‑2 agonist (SABA) for rapid relief of bronchospasm, and health bodies and reviews say it is “safe and very effective if...
Patients commonly reduce or manage medication side effects by talking with their prescriber or pharmacist, changing timing or dose, adding supportive treatments (like anti-nausea agents or hydration),...
Reclassification dates vary widely by policy area and jurisdiction: some processes run on fixed cycles (e.g., Georgia High School Association reclassification cycles for 2026–28 with deadlines in Nove...